Alaye siwaju sii ― Yoruba

Scleroderma jẹ arun ti o ṣọwọn ti o kan awọn ara asopọ, ti n ṣafihan bi awọ lile ati nigbakan ni ipa awọn ẹya miiran ti ara. Awọn oriṣi akọkọ meji lo wa: systemic sclerosis , eyiti o jẹ pẹlu líle awọ ara ati awọn ara inu, ati localized scleroderma , ti a tun mọ ni morphea, eyiti o maa wa ni opin si awọ ara ati awọn awọ ti o wa labẹ rẹ, pẹlu ilana ti ko dara ati opin ara ẹni. Botilẹjẹpe scleroderma ti agbegbe jẹ loorekoore ati idi rẹ ko ṣe akiyesi, iwadii aipẹ ṣe imọran pe o tun le ni ipa lori awọn ara inu ati ja si ọpọlọpọ awọn ọran ilera. Itọju tete jẹ pataki lati yago fun awọn ilolu, fun iwulo agbara ti localized scleroderma.
Scleroderma is a rare connective tissue disease that is manifested by cutaneous sclerosis and variable systemic involvement. Two categories of scleroderma are known: systemic sclerosis, characterized by cutaneous sclerosis and visceral involvement, and localized scleroderma or morphea which classically presents benign and self-limited evolution and is confined to the skin and/or underlying tissues. Localized scleroderma is a rare disease of unknown etiology. Recent studies show that the localized form may affect internal organs and have variable morbidity. Treatment should be started very early, before complications occur due to the high morbidity of localized scleroderma.

Morphea , tun mọ bi scleroderma ti agbegbe, jẹ arun autoimmune ti o ṣọwọn ti o kan àsopọ asopọ. O le ṣe afihan ni awọn ọna oriṣiriṣi, ati pe ko wọpọ, pẹlu awọn iṣẹlẹ 0. 4 - 2. 7 fun eniyan 100,000 ni ọdun kọọkan. Morphea nigbagbogbo ni a rii ni awọn ọmọde laarin ọdun 2 si 14, ati pe o maa n kan awọn ọmọbirin ni igbagbogbo ju awọn ọmọkunrin lọ.
Morphea (localized scleroderma) is a rare autoimmune connective tissue disease with variable clinical presentations, with an annual incidence of 0.4-2.7 cases per 100,000. Morphea occurs most frequently in children aged 2-14 years, and the disease exhibits a female predominance.